New atlas that charts tumor cell diversity could guide personalized therapy for head and neck cancer

Head and neck squamous cell carcinomas (HNSCC) are the seventh-most prevalent form of cancer and are associated with human ...
Business Wire

Deciphera Receives European Commission Approval of ROMVIMZA™ (vimseltinib) for the Treatment of Tenosynovial Giant Cell Tumor (TGCT)

OSAKA, Japan & WALTHAM, Mass.--(BUSINESS WIRE)--Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today ...
Business Wire

Deciphera Announces Positive CHMP Opinion for ROMVIMZA™ (vimseltinib) for the Treatment of Tenosynovial Giant Cell Tumor (TGCT)

OSAKA, Japan & WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, LLC, a biopharmaceutical company focused on discovering, developing, and commercializing ...
Medscape

FDA Approves Vimseltinib for Tenosynovial Giant Cell Tumors

The US Food and Drug Administration has approved vimseltinib (Romvimza, Deciphera Pharmaceuticals, LLC) to treat adult patients with symptomatic tenosynovial giant cell tumors (TGCT) who will not ...
Hosted on MSN

New drug targets cancer cell mitochondria to halt head and neck tumors

Researchers at MUSC Hollings Cancer Center have discovered a potentially powerful weapon in the fight against head and neck cancers. The new drug, still in preclinical studies, attacks cancer cells ...
Hosted on MSN

CRISPR gene editing breakthrough eliminates 50% of head, neck tumors

Head and neck cancers often begin in the mouth, throat, or voice box. They're among the most common cancers in the world, affecting over half a million people each year and causing about 300,000 ...